Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

NCT05470270 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Theravia